Singapore’s ClavystBio seeks as much as a tripling of life science startup returns
A researcher works in a laboratory at life sciences investor ClavystBio’s premises in Singapore. (Photo by Dylan Loh)
DYLAN LOH
December 18, 2025 09:29 JST
SINGAPORE — A Temasek Holdings venture capital arm that specializes in life sciences is aiming to reap long-term profits from investments in biotechnology startups that are developing treatments for diseases such as cancer, particularly those leveraging artificial intelligence to achieve medical breakthroughs.